Aller au contenu principal
Profil bibliographique

Sofie-Katrin Kadel

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

3Publications signalées
0Citations signalées
0Affiliations récentes

Les domaines associés

CAR-T cell therapy researchNeuroinflammation and Neurodegeneration MechanismsParkinson's Disease Mechanisms and TreatmentsSingle-cell and spatial transcriptomicsBiomedical Ethics and Regulation

Les publications récentes

Accès ouvert 2026 other OpenAlex

Data from Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy

Sofie-Katrin Kadel, Lukas Scheller, Alexander M. Leipold, Tobias Krammer et autres

Abstract We report a fatal case of parkinsonism following treatment with ciltacabtagene autoleucel (cilta-cel). To investigate underlying mechanisms, we performed a multipronged longitudinal analysis using single-cell RNA (scRNA)/T-cell receptor (TCR) sequencing, flow cytometry, and cytokine measurements including cerebrospinal fluid (CSF) and peripheral …

0 citations
Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figures S1-S8 from Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy

Sofie-Katrin Kadel, Lukas Scheller, Alexander M. Leipold, Tobias Krammer et autres

Supplementary Figure 1 illustrates the longitudinal course of myeloma-related parameters throughout the patient’s treatment, as well as the therapeutic response assessed by ^68Ga-Pentixafor PET/CT. Supplementary Figure 2 shows the BCMA-CAR integration sites in the patient’s genome and their distribution Supplementary Figure 3 …

0 citations
Accès ouvert 2026 other OpenAlex

Table S1-S15 from Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy

Sofie-Katrin Kadel, Lukas Scheller, Alexander M. Leipold, Tobias Krammer et autres

Supplementary Table 1 summarizes the lines of therapy administered prior to CAR T cell therapy. Supplementary Table 2 presents myeloma parameters and additional laboratory findings obtained immediately before the initiation of lymphodepleting chemotherapy of the index patient. Supplementary Table 3 details the …

0 citations

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.